> top > docs > PubMed:29291351 > annotations

PubMed:29291351 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-83 Sentence denotes The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.
T2 84-192 Sentence denotes Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead to advanced liver diseases.
T3 193-313 Sentence denotes Lack of effective pharmacotherapies for NASH is largely attributable to an incomplete understanding of its pathogenesis.
T4 314-399 Sentence denotes The deubiquitinase cylindromatosis (CYLD) plays key roles in inflammation and cancer.
T5 400-471 Sentence denotes Here we identified CYLD as a suppressor of NASH in mice and in monkeys.
T6 472-577 Sentence denotes CYLD is progressively degraded upon interaction with the E3 ligase TRIM47 in proportion to NASH severity.
T7 578-775 Sentence denotes We observed that overexpression of Cyld in hepatocytes concomitantly inhibits lipid accumulation, insulin resistance, inflammation and fibrosis in mice with NASH induced in an experimental setting.
T8 776-945 Sentence denotes Mechanistically, CYLD interacts directly with the kinase TAK1 and removes its K63-linked polyubiquitin chain, which blocks downstream activation of the JNK-p38 cascades.
T9 946-1154 Sentence denotes Notably, reconstitution of hepatic CYLD expression effectively reverses disease progression in mice with dietary or genetically induced NASH and in high-fat diet-fed monkeys predisposed to metabolic syndrome.
T10 1155-1324 Sentence denotes Collectively, our findings demonstrate that CYLD mitigates NASH severity and identify the CYLD-TAK1 axis as a promising therapeutic target for management of the disease.
T1 0-83 Sentence denotes The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.
T2 84-192 Sentence denotes Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead to advanced liver diseases.
T3 193-313 Sentence denotes Lack of effective pharmacotherapies for NASH is largely attributable to an incomplete understanding of its pathogenesis.
T4 314-399 Sentence denotes The deubiquitinase cylindromatosis (CYLD) plays key roles in inflammation and cancer.
T5 400-471 Sentence denotes Here we identified CYLD as a suppressor of NASH in mice and in monkeys.
T6 472-577 Sentence denotes CYLD is progressively degraded upon interaction with the E3 ligase TRIM47 in proportion to NASH severity.
T7 578-775 Sentence denotes We observed that overexpression of Cyld in hepatocytes concomitantly inhibits lipid accumulation, insulin resistance, inflammation and fibrosis in mice with NASH induced in an experimental setting.
T8 776-945 Sentence denotes Mechanistically, CYLD interacts directly with the kinase TAK1 and removes its K63-linked polyubiquitin chain, which blocks downstream activation of the JNK-p38 cascades.
T9 946-1154 Sentence denotes Notably, reconstitution of hepatic CYLD expression effectively reverses disease progression in mice with dietary or genetically induced NASH and in high-fat diet-fed monkeys predisposed to metabolic syndrome.
T10 1155-1324 Sentence denotes Collectively, our findings demonstrate that CYLD mitigates NASH severity and identify the CYLD-TAK1 axis as a promising therapeutic target for management of the disease.

sonoma

Id Subject Object Predicate Lexical cue
T-0 28-43 GENE denotes cylindromatosis
T-1 114-118 DISEASE denotes NASH
T-2 160-164 REG denotes lead
T-3 233-237 DISEASE denotes NASH
T-4 333-348 GENE denotes cylindromatosis
T-5 350-354 GENE denotes CYLD
T-6 419-423 GENE denotes CYLD
T-7 429-439 NEGREG denotes suppressor
T-8 443-447 DISEASE denotes NASH
T-9 472-476 GENE denotes CYLD
T-10 494-502 NEGREG denotes degraded
T-11 539-545 GENE denotes TRIM47
T-12 563-567 DISEASE denotes NASH
T-13 613-617 GENE denotes Cyld
T-14 647-655 NEGREG denotes inhibits
T-15 735-739 DISEASE denotes NASH
T-16 793-797 GENE denotes CYLD
T-17 833-837 GENE denotes TAK1
T-18 842-849 NEGREG denotes removes
T-19 892-898 NEGREG denotes blocks
T-20 981-985 GENE denotes CYLD
T-21 1074-1081 REG denotes induced
T-22 1082-1086 DISEASE denotes NASH
T-23 1120-1131 REG denotes predisposed
T-24 1199-1203 GENE denotes CYLD
T-25 1214-1218 DISEASE denotes NASH
R-0 T-1 T-2 ThemeOf NASH,lead
R-1 T-6 T-7 ThemeOf CYLD,suppressor
R-2 T-6 T-8 ThemeOf CYLD,NASH
R-3 T-7 T-8 ThemeOf suppressor,NASH
R-4 T-9 T-10 ThemeOf CYLD,degraded
R-5 T-9 T-12 ThemeOf CYLD,NASH
R-6 T-10 T-11 ThemeOf degraded,TRIM47
R-7 T-10 T-12 ThemeOf degraded,NASH
R-8 T-11 T-12 ThemeOf TRIM47,NASH
R-9 T-13 T-14 ThemeOf Cyld,inhibits
R-10 T-13 T-15 ThemeOf Cyld,NASH
R-11 T-14 T-15 ThemeOf inhibits,NASH
R-12 T-18 T-19 ThemeOf removes,blocks
R-13 T-20 T-22 ThemeOf CYLD,NASH
R-14 T-21 T-22 ThemeOf induced,NASH
R-15 T-24 T-25 ThemeOf CYLD,NASH